Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban.
In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity.
Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia.
The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally.
The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland.
As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 21 | 3.52 Increased by +9.32% | 3.14 Increased by +12.04% |
| Feb 4, 21 | 2.96 Increased by +9.23% | 2.56 Increased by +15.48% |
| Oct 29, 20 | 3.24 Increased by +16.13% | 2.60 Increased by +24.58% |
| Jul 30, 20 | 3.11 Increased by +17.80% | 2.58 Increased by +20.52% |
| May 6, 20 | 3.22 Increased by +34.73% | 2.71 Increased by +18.67% |
| Jan 30, 20 | 2.71 Increased by +26.64% | 2.61 Increased by +3.86% |
| Oct 23, 19 | 2.79 Increased by +38.12% | 2.48 Increased by +12.69% |
| Jul 24, 19 | 2.64 Increased by +27.54% | 2.34 Increased by +12.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 21 | 1.64 B Increased by +13.27% | 636.00 M Increased by +14.06% | Increased by +38.86% Increased by +0.70% |
| Dec 31, 20 | 1.59 B Increased by +14.99% | 535.80 M Decreased by -39.73% | Increased by +33.66% Decreased by -47.59% |
| Sep 30, 20 | 1.59 B Increased by +25.78% | 578.10 M Increased by +23.63% | Increased by +36.39% Decreased by -1.71% |
| Jun 30, 20 | 1.44 B Increased by +20.05% | -1.07 B Decreased by -332.30% | Decreased by -73.94% Decreased by -293.49% |
| Mar 31, 20 | 1.44 B Increased by +26.69% | 557.60 M Decreased by -5.15% | Increased by +38.59% Decreased by -25.14% |
| Dec 31, 19 | 1.38 B Increased by +22.63% | 889.00 M Increased by +2.08 K% | Increased by +64.22% Increased by +1.71 K% |
| Sep 30, 19 | 1.26 B Increased by +23.05% | 467.60 M Increased by +41.31% | Increased by +37.02% Increased by +14.84% |
| Jun 30, 19 | 1.20 B Increased by +15.15% | 459.80 M Increased by +200.52% | Increased by +38.21% Increased by +187.30% |